What it's for (Indications)
- Lansoprazole is a proton pump inhibitor (PPI) indicated for the short-term treatment of active duodenal ulcers, typically for up to four weeks.
- It is also approved for the short-term treatment and maintenance of healing of erosive esophagitis (EE), with initial treatment usually lasting up to eight weeks, followed by maintenance therapy for up to 12 months.
- Furthermore, lansoprazole is indicated for the short-term treatment of active benign gastric ulcers for up to eight weeks.
- It plays a crucial role in the eradication of *Helicobacter pylori* (H.
- pylori) infection to reduce the risk of duodenal ulcer recurrence, usually in combination with appropriate antibiotics.
- Additionally, lansoprazole is utilized for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome, where it effectively controls gastric acid secretion.
- The drug is also approved for the short-term treatment of gastroesophageal reflux disease (GERD) symptoms in adults and adolescents, often for a period of up to eight weeks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical adult dosage of lansoprazole varies significantly based on the specific indication and patient response. For the treatment of active duodenal ulcers, a common regimen involves 15 mg once daily for four weeks. In the case of erosive esophagitis, the standard dose is often 30 mg once daily for up to eight weeks for healing, with maintenance doses typically being 15 mg daily for up to 12 months. For active benign gastric ulcers, a dosage of 30 mg once daily for up to eight weeks is usually prescribed. When used as part of a regimen to eradicate *Helicobacter pylori*, lansoprazole is typically administered at 30 mg twice daily for 10 to 14 days, in conjunction with specific antibiotics such as amoxicillin and clarithromycin. For pathological hypersecretory conditions, including Zollinger-Ellison syndrome, the initial adult dosage is usually 60 mg once daily, with subsequent dosage adjustments based on individual acid output and clinical response. Doses exceeding 120 mg daily should be divided. For symptomatic GERD, 15 mg once daily for up to eight weeks is often sufficient. Pediatric dosages are weight-based and indication-specific, requiring careful titration by a healthcare professional. |
Safety & Warnings
Common Side Effects
- Lansoprazole, like other proton pump inhibitors, is generally well-tolerated, but can cause a range of side effects.
- Common adverse reactions reported in clinical trials include headache, nausea, diarrhea, constipation, and abdominal pain.
- Less frequently, patients may experience dizziness, fatigue, skin rash, or dry mouth.
- More serious, albeit rare, adverse effects are associated with long-term use.
- These include an increased risk of *Clostridium difficile*-associated diarrhea (CDAD), particularly in hospitalized patients, due to alterations in gut microbiota.
- Long-term PPI therapy, especially at high doses, has been linked to an increased risk of bone fractures (hip, wrist, or spine) due to potential interference with calcium absorption.
- Additionally, there is a risk of hypomagnesemia, characterized by low magnesium levels, which can lead to serious adverse events such as arrhythmias, seizures, and tetany; this often requires magnesium supplementation and PPI discontinuation.
- Other long-term risks include the development of fundic gland polyps, vitamin B12 deficiency, and acute interstitial nephritis.
- Rarely, severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome have been reported, necessitating immediate medical attention.
Serious Warnings
- Black Box Warning: Lansoprazole does not carry a formal FDA Black Box Warning. However, several serious warnings and precautions are associated with its use, particularly with long-term therapy, which healthcare providers and patients must be aware of. Prolonged treatment (e.g., longer than one year) with lansoprazole and other proton pump inhibitors has been linked to an increased risk of bone fractures of the hip, wrist, or spine, predominantly in the elderly or in the presence of other established risk factors for osteoporosis. This risk necessitates careful consideration, especially for vulnerable populations. Furthermore, cases of hypomagnesemia have been reported in patients on PPIs for at least three months, but often after a year or more of therapy. This condition, characterized by low serum magnesium levels, can be severe and may lead to serious adverse events such as cardiac arrhythmias, seizures, and tetany, requiring prompt magnesium supplementation and, in some cases, discontinuation of the PPI. Acute interstitial nephritis has been observed in patients taking lansoprazole at any time during therapy and may manifest with non-specific symptoms such as fever, rash, and malaise. *Clostridium difficile*-associated diarrhea (CDAD) risk is also elevated, ranging in severity from mild diarrhea to fatal colitis. Fundic gland polyps, typically asymptomatic, have been found to increase with long-term PPI use, though they are generally benign. PPI therapy may also mask symptoms of gastric malignancy, thus delaying diagnosis. Therefore, patients with persistent symptoms despite treatment should undergo further diagnostic evaluation.
- Lansoprazole should be used with caution, particularly in certain patient populations and with long-term therapy.
- Patients should be advised about the potential for increased risk of *Clostridium difficile*-associated diarrhea, which can range from mild diarrhea to fatal colitis.
- Long-term use of lansoprazole (e.
- g.
- , beyond one year) may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine, particularly in elderly patients or those with other risk factors for fracture.
- Hypomagnesemia has been reported in patients treated with PPIs for at least three months, often after a year or more of therapy, and may require magnesium supplementation or discontinuation of the PPI.
- Co-administration with clopidogrel should be approached with caution, as lansoprazole can reduce the antiplatelet effect of clopidogrel by inhibiting CYP2C19, the enzyme responsible for its activation, potentially increasing the risk of thrombotic events.
- Acute interstitial nephritis has been observed in patients taking PPIs, including lansoprazole, at any point during therapy.
- There is also a risk of developing fundic gland polyps with long-term use.
- Patients should not stop lansoprazole abruptly without consulting a healthcare provider due to the potential for rebound acid hypersecretion.
- PPI therapy may mask symptoms of gastric malignancy, thus delaying diagnosis, and therefore, further diagnostic evaluation is warranted in patients with persistent symptoms.
How it Works (Mechanism of Action)
Lansoprazole exerts its therapeutic effects by irreversibly inhibiting the gastric H+/K+-ATPase, also known as the proton pump, located on the secretory surface of the parietal cells in the stomach. This proton pump is the final common pathway for acid secretion. As a substituted benzimidazole, lansoprazole is a prodrug that becomes activated in the acidic environment of the parietal cell's secretory canaliculi. Once activated, it covalently binds to sulfhydryl groups of cysteine residues on the H+/K+-ATPase enzyme, thereby blocking the exchange of potassium ions for hydrogen ions and preventing the transport of acid into the gastric lumen. This inhibition is dose-dependent and results in a profound and long-lasting decrease in basal and stimulated gastric acid secretion, irrespective of the stimulus. The irreversible nature of this binding means that acid secretion only resumes when new proton pumps are synthesized and incorporated into the parietal cell membrane, which typically takes several days. This mechanism provides sustained acid suppression, crucial for the healing of acid-related gastrointestinal conditions such as ulcers and erosive esophagitis, and the management of GERD.